drugset / Trial / NCT00791765

Moderate to Severe Plaque Psoriasis With Scalp Involvement

NCT00791765

Phase 4 Completed 124 enrolled Amgen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if etanercept is effective in the treatment of scalp involvement in moderate to severe plaque psoriasis.

Timeline

Start
2008-10
Primary completion
2010-01
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg Subcutaneous

Indications